Australia's NeuroScientific Biopharma surges on stroke treatment drug hopes

Neuroscientific Biopharmaceuticals

09/09/2022 05:40

** Shares of Australia's NeuroScientific Biopharmaceuticals
Ltd  NSB.AX  rise as much as 19.32% to A$0.105 in their biggest
intraday pct gain since June 15
    ** Peptide-based pharmaceutical drugs developer says it will
commence review of operations and make changes to ensure EmtinB
stroke treatment drug continues to progress to commercialisation
 urn:newsml:reuters.com:*:nASX78y6M3
    ** NSB stock hit a record low on Wednesday after planned
phase-I clinical trial for EmtinB was rejected  urn:newsml:reuters.com:*:nL4N30E1CE
    ** Co announces resignation of CEO and MD Matt Liddelow,
says it will commence search for new CEO with pharmaceutical
development experience 
    ** Nearly 1.7 mln shares change hands, vs the 30-day average
 of ~550,000 shares
    ** Stock down 73.73% this year, as of last close

 (Reporting By Udbhav Krishna P in Bengaluru)
 ((UdbhavKrishna.P@Thomsonreuters.com))